<DOC>
	<DOCNO>NCT01538667</DOCNO>
	<brief_summary>The purpose study characterize variability extent deposition ciprofloxacin respiratory tract healthy subject comparison patient chronic lung disease inhalation single 50 mg dry powder dose contain 32 mg active substance . In addition safety pharmacokinetics ciprofloxacin evaluate . In study radiolabeled substance administer scintigraphy image technique use demonstrate lung deposition visually . In healthy subject additional pharmacokinetic method use calculate lung deposition indirectly base pharmacokinetic data derive plasma . For purpose inhale separate occasion another dose ciprofloxacin ingest activated charcoal . The latter serf bind ciprofloxacin swallow inhalation maneuver gastrointestinal ( GI ) tract , thus prevent uptake blood ( charcoal block ) . Safety investigation focus local tolerability lung . Pharmacokinetics see body absorbs , distributes , break get rid study drug . Results study use show drug distribute human lung .</brief_summary>
	<brief_title>Study Characterize Lung Deposition , Pharmacokinetics , Safety Tolerability Single Inhalations Radiolabeled Ciprofloxacin Dry Powder Healthy Subjects Patients With Chronic Lung Diseases</brief_title>
	<detailed_description />
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Inclusion criterion subject : Understanding study write informed consent prior studyrelated procedure Additional inclusion criterion healthy subject : Age : 18 65 year ( inclusive ) screen visit Males Non exsmokers smoke &lt; 5 packyears stop smoke &gt; 1 year prior screen visit Results laboratory test within normal range ; minor deviation acceptable provide judge clinically significant investigator Additional inclusion criterion patient COPD ( chronic obstructive pulmonary disease ) : Age : 40 70 year ( inclusive ) screen visit Males females All patient must diagnosis COPD Stage II III accord GOLD ( Global Initiative Chronic Obstructive Lung Disease ) Classification ( postbronchodilator force expiratory volume 1 second ( FEV1 ) : 80 % &gt; FEV1 ≥ 30 % predict value postbronchodilator FEV1/FVC ≤ 70 % ( FVC = force vital capacity ) Minimum smoke history 10 packyears Additional inclusion criterion patient bronchiectasis : Age : 18 75 year ( inclusive ) screen visit Males females Diagnosis bronchiectasis Known hypersensitivity , allergy intolerance study drug formulation ingredient Febrile illness within 1 week prior screen visit Concomitant severe disease ( judge investigator ) diseases contraindication use inhale ciprofloxacin Use ciprofloxacin within 30 day screen visit Use systemic topical medicine substance oppose study objective might influence , e.g . systemic administration antibiotic subject renal excretion ( e.g . betalactam antibiotic , levofloxacin , ofloxacin , etc . ) , furosemide antacid Donation 450 mL blood within 4 week screen visit Clinically relevant finding ECG Clinically relevant abnormal laboratory value suggest unknown disease require clinical investigation Participation another clinical study le 8 week prior screen visit Pulmonary exacerbation within 6 week prior screen History lung transplant lung surgery thoracic surgery wait list Additional exclusion criterion healthy subject Lung function measurement outside normal limit ( Normal value : FEV1/FVC &gt; 70 % FEV1 FVC &gt; 80 % predict ) Additional exclusion criterion patient Regular use daytime oxygen therapy Diagnosis bronchial asthma Diagnosis clinically evident bronchiectasis ( COPD patient ) Total blood eosinophil count &gt; /= 600/mm3 . Completion pulmonary rehabilitation program six week prior screen visit current participation pulmonary rehabilitation program Change dose type medication within 4 week prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lung</keyword>
	<keyword>Scintigraphy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Inhalation</keyword>
	<keyword>Ciprofloxacin</keyword>
</DOC>